#antiviral

However, researchers saw little difference across racial groups in HBV treatment initiation among those who were eligible.

The first studies, launched on July 31, will focus on viral persistence and cognitive dysfunction.

Most study participants achieved viral suppression with minimal changes in kidney function or bone density.

Most people who stopped long-term nucleoside/nucleotide analogs did not need to restart treatment.

Study findings suggest people with chronic liver disease should be prioritized for booster shots.

Before they get COVID, people over 65 should have a plan for accessing antiviral treatment.

The antiviral treatment reduced the risk of hospitalization or death from SARS-CoV-2 Omicron variants in older adults by 44%.

The antiviral treatment is safe and effective for pediatric patients ages 12 and up.

People with HIV are at greater risk for hepatitis B but are less likely to get vaccinated and respond to vaccines.

The new drug reduced HDV viral load and lowered liver enzyme levels in people with hepatitis B and D.

Paxlovid and molnupiravir can reduce the risk of severe COVID-19, but they must be started within five days of symptom onset.

Molnupiravir is authorized for people at high risk for severe COVID-19 when other treatment options are not available.

Paxlovid, which reduces the risk of hospitalization or death by about 90%, is expected to be a game-changer.

The new drugs must be used within a narrow window of time after developing symptoms.

Molnupiravir reduces severe illness and death, but it must be started within days after developing symptoms.

Post-exposure and pre-exposure prophylaxis could be a game-changer for immunocompromised people.